Figure 3

Clinical outcome and suppression of viral load in a time frame of 96 weeks of follow-up therapy (illustrated as box plot figure). Median viral loads are illustrated in bold lines in between the upper- and lower quartile. Group B (ATV and/or SQV plus LPV or APV containing treatment) show a higher long-term success rate after 96 weeks of follow-up therapy in comparison to group A (ATV and or SQV without L76V-selecting drug).